This database contains 125 studies, archived under the term: "Alzheimer"
Click here to filter this large number of results.
Multivariate spatial covariance analysis of 99mTc-exametazime SPECT images in dementia with Lewy bodies and Alzheimer’s disease: utility in differential diagnosis
Colloby, Sean J,
Taylor, John-Paul,
Davison, Christopher M,
Lloyd, Jim J,
Firbank, Michael J,
McKeith, Ian G,
O'Brien, John T
We examined (99m)Tc-exametazime brain blood flow single-photon emission computed tomography (SPECT) images using a spatial covariance analysis (SCA) approach to assess its diagnostic value in distinguishing dementia with Lewy bodies (DLB) from Alzheimer’s disease (AD). Voxel SCA was simultaneously applied to a set of preprocessed images (AD, n=40; DLB, n=26), generating a series of eigenimages […]
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer’s disease: a multicenter, randomized, open-label, parallel-group study
Choi, Seong Hye,
Park, Kyung Won,
Na, Duk L.,
Han, Hyun Jeong,
Kim, Eun-Joo,
Shim, Yong S.,
Lee, Jae-Hong,
The EXPECT Study Group,
Objective: To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer’s disease (AD).; Research Design and Methods: In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 rivastigmine patch for 4 weeks, then a […]
The mini-mental Parkinson’s (MMP) as a cognitive screening tool in people with Parkinson’s disease
Caslake, Robert,
Summers, Fiona,
McConachie, Douglas,
Ferris, Catriona,
Gordon, Joanna,
Harris, Clare,
Caie, Linda,
Counsell, Carl
Background: Cognitive decline is common in Parkinson’s disease (PD) but may not be adequately identified by the mini-mental state examination (MMSE), which is better suited to Alzheimer’s disease. The mini-mental Parkinson (MMP) examination is a cognitive screening tool designed in French specifically for PD. We aimed to establish the validity and reliability of the English […]
Diagnosis of Alzheimer’s disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire
Carcaillon, L.,
Berrut, G.,
Sellal, F.,
Dartigues, J. F.,
Gillette, S.,
Pere, J. J.,
Bourdeix, I.
Background: Patients with Alzheimer’s disease (AD) who deteriorate rapidly are likely to have a poorer prognosis. There is a clear need for a clinical assessment tool to detect such a decline in newly diagnosed patients.; Objective: To identify the predictive factors of rapid cognitive decline (RCD) in a cohort of patients with mild to moderate […]
Validation of Alzheimer’s disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer’s Disease Neuroimaging Initiative (E-ADNI)
Buerger, Katharina,
Frisoni, Giovanni,
Uspenskaya, Olga,
Ewers, Michael,
Zetterberg, Henrik,
Geroldi, Cristina,
Binetti, Giuliano,
Johannsen, Peter,
Rossini, Paolo Maria,
Wahlund, Lars-Olof,
Vellas, Bruno,
Blennow, Kaj,
Hampel, Harald
Background: Alzheimer’s Disease Neuroimaging Initiatives (“ADNI”) aim to validate neuroimaging and biochemical markers of Alzheimer’s disease (AD). Data of the pilot European-ADNI (E-ADNI) biological marker programme of cerebrospinal fluid (CSF) and plasma candidate biomarkers are reported.; Methods: Six academic EADC centres recruited 49 subjects (healthy controls, subjects with mild cognitive impairment (MCI) and AD). We […]
Olive oil and cognition: results from the three-city study
Berr, Claudine,
Portet, Florence,
Carrière, Isabelle,
Akbaraly, Tasnime N.,
Feart, Catherine,
Gourlet, Véronique,
Combe, Nicole,
Barberger-Gateau, Pascale,
Ritchie, Karen
Background: Olive oil is a major component of the Mediterranean diet suggested to be beneficial to counteract Alzheimer’s disease.; Aim Of the Study: Our objective was to examine the association between olive oil use, cognitive deficit and cognitive decline in a large elderly population.; Methods: We followed 6,947 subjects with a brief baseline food frequency […]
Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial
Banerjee, Sube,
Hellier, Jennifer,
Dewey, Michael,
Romeo, Renee,
Ballard, Clive,
Baldwin, Robert,
Bentham, Peter,
Fox, Chris,
Holmes, Clive,
Katona, Cornelius,
Knapp, Martin,
Lawton, Claire,
Lindesay, James,
Livingston, Gill,
McCrae, Niall,
Moniz-Cook, Esme,
Murray, Joanna,
Nurock, Shirley,
Orrell, Martin,
O'Brien, John,
Poppe, Michaela,
Thomas, Alan,
Walwyn, Rebecca,
Wilson, Kenneth,
Burns, Alistair
Background: Depression is common in dementia but the evidence base for appropriate drug treatment is sparse and equivocal. We aimed to assess efficacy and safety of two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.; Methods: We undertook the parallel-group, double-blind, placebo-controlled, Health Technology Assessment Study of the Use of Antidepressants […]